表紙
市場調査レポート

欧州のドラッグデリバリー技術(定量吸入器、無針注射器、自動注射器、鼻内噴霧器、経皮パッチ、ネブライザー、薬物注入ポンプ、薬剤溶出ステント、徐放薬、眼球内移植)市場の予測

European Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free injectors, Auto-injectors, Nasal sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts to 2017

発行 MarketsandMarkets 商品コード 274481
出版日 ページ情報 英文 300 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
欧州のドラッグデリバリー技術(定量吸入器、無針注射器、自動注射器、鼻内噴霧器、経皮パッチ、ネブライザー、薬物注入ポンプ、薬剤溶出ステント、徐放薬、眼球内移植)市場の予測 European Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free injectors, Auto-injectors, Nasal sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts to 2017
出版日: 2013年06月24日 ページ情報: 英文 300 Pages
概要

欧州のドラッグデリバリー技術市場は2012年の時点で399億ドル規模。技術は年を追うごとに著しい進歩を続けています。また、老齢人口の増加も顕著です。世界経済フォーラム(WEF)の2012年発表レポートによると、スイスの老齢人口比は23%。これが2030年には32%、2050年には37%に拡大する見通しであり、これは斬新かつ使いやすいドラッグデリバリーシステムに大きな機会が訪れることを意味します。

当レポートでは、こうした欧州のドラッグデリバリー技術市場に注目し、ドイツ、フランス、英国、スペイン、イタリア、ロシアほかの地域を対象に、その推移と動態を展望しながら、各技術および各国の現況、市場予測数値をまとめるほか、競合環境や主要参入企業についての最新情報を集めて、概略以下の構成でお届けします。

第1章 イントロダクション

  • 重要所見
  • レポート内容
  • 調査対象市場
  • 推奨読者層
  • 調査方法
    • 市場規模
    • 市場シェア
    • 二次情報源から得られたデータの主要ポイント
    • 一次情報源から得られたデータの主要ポイント
    • 前提

第2章 エグゼクティブサマリー

第3章 市場概要

  • イントロダクション
  • 市場動態
    • 推進要因
      • 「特許の崖」と競争激化で上昇する利用率
      • 向上する患者の薬剤服用順守および受容姿勢がドラッグデリバリーシステム市場の弾みに
      • 高まる小児および老齢患者重視の姿勢が全体成長の追い風に
      • がんや糖尿病など慢性疾患の発生率上昇で拡大するドラッグデリバリー技術需要
      • 東欧諸国やロシアで比較的高い若年死亡率が示唆するよりよい医療の必要性
    • 抑制要因
      • 薬物事故やリコールが市場発展を阻害
      • 成長を妨げる技術障壁
    • 機会
      • 医薬品企業とドラッグデリバリー会社の共同作業
      • 自己投与と在宅介護ドラッグデリバリー装置
      • 拡大するドラッグデリバリー技術の治療用途
    • 標的ドラッグデリバリー
      • 受動型システムは標的ドラッグデリバリーに対して6割の貢献
      • 主要用途をがん治療に持つ能動型標的ドラッグデリバリー
      • これまでにない標的ドラッグデリバリーに注目する企業
    • 緊急課題
      • 真に適正な提携関係
      • 薬物の生物学的利用能向上
  • 規制問題
    • 欧州共同体が定める規制の枠組み
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • ロシア
  • 欧州共同体における報酬の仕組み
  • Porterのファイブフォース分析
  • バリューチェーン分析
  • 市場シェア分析
    • 経肺ドラッグデリバリー
    • 注射型ドラッグデリバリー

第4章 世界のドラッグデリバリー市場 - 技術別

  • イントロダクション
  • 機会マトリクス
  • 経口ドラッグデリバリー
  • 経肺ドラッグデリバリー
  • 経皮ドラッグデリバリー
  • 注射型ドラッグデリバリー
  • 眼内ドラッグデリバリー
  • 鼻内ドラッグデリバリー
  • 局所ドラッグデリバリー
  • 移植型ドラッグデリバリー
  • 経粘膜ドラッグデリバリー

第5章 地域分析

  • イントロダクション
  • ドイツ
  • フランス
  • 英国
  • スペイン
  • イタリア
  • ロシア
  • その他の国々

第6章 競合環境

  • イントロダクション
  • 新製品発売
  • 協定、協力、合弁事業、提携関係
  • M&A
  • その他の展開

第11章 企業プロフィール(概要、財務、製品・サービス、戦略、事業展開)

目次
Product Code: BT 2060

The European drug delivery market was worth $39.9 billion in the year 2012. The drug delivery technology market is segmented on the basis of route of administration into nine categories - oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. Over the years, drug delivery technologies have grown phenomenally from plain drug reformulation and release technologies, to innovative platforms that hold a huge potential for the effective delivery of biologicals and novel drugs.

Patent expiries of certain blockbuster drugs, growing demand for self-administration and home healthcare devices, rising incidence of chronic diseases such as cardiovascular diseases, diabetes and cancer and growing focus on pediatric and geriatric patients are accelerating the growth of this market. However, drug failures and recalls and technical barriers are estimated to hamper the growth of this market. Over the years, drug delivery technologies have grown phenomenally from plain drug reformulation and release technologies to innovative platforms that hold a huge potential for the effective delivery of biologicals and novel drugs.

The growing number of elderly persons is a large consumer of home care drug delivery devices. Expanding applications of drug delivery into niche therapeutic areas, strategic collaborations and self-administration and home care drug delivery devices represent vast opportunities for key players in this market. According to a 2012 report published by the World Economic Forum (WEF), the total geriatric population of Switzerland (aged 60 years and older) was 23% of the total population. This number is expected to increase to 32% by 2030 and to 37% by 2050. An increase in the number of geriatric patients and rise in demand for convenient drug delivery options pose major opportunities for the development of innovative and easy-to-use drug delivery systems.

The geographies covered in this study are Germany, France, United Kingdom, Spain, Italy, Russia and Rest of Europe (RoE). Germany is the largest market for drug delivery, followed by France and the U.K. However, these countries are expected to grow at a slower pace than Russia and RoE, primarily due to a certain amount of saturation in the market. The latter markets are poised to register maximum growth over the next five years, owing to the expansion of these economies, increase in disposable income, development of healthcare infrastructure, increasing penetration of health insurance, and rising prevalence of chronic diseases.

Scope of the Report

This research report categorizes the European drug delivery market into oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the drug delivery markets is comprehensively analyzed at a granular level by geography (Germany, France, United Kingdom, Spain, Italy, Russia and Rest of Europe) to provide in-depth information on the European scenario of this market.

European drug delivery market, by technologies

  • Oral
    • Controlled Release
    • Orodispersible Tablets (ODT) and Taste Masking
    • Others
  • Pulmonary
    • Dry Powder Inhalers
    • Metered Dose Inhalers
    • Nebulizers
  • Transdermal
    • Passive
      • Reservoir System
      • Matrix System
    • Active
      • Iontophoresis
      • Microporation
      • Others
  • Injectable
    • Conventional Injection Devices
      • Fillable Syringes
      • Prefilled Syringes
    • Self-injection Devices
      • Needle-free Injectors
      • Auto-injectors or Safety Syringe Devices
      • Pen Injectors
    • Others
  • Ocular
    • Eye Drops
    • Ointment and Gel
    • Others
  • Nasal
    • Nasal Drops
    • Nasal Sprays
    • Nasal Inhalers
    • Others
  • Topical
    • Liquid Formulations
    • Semi-solid Formulations
    • Solid Formulations
  • Implantable
    • Drug Eluting Stents
    • Implantable Infusion Pumps
    • Intravitreal Implants
    • Brachytherapy Seeds
    • Contraceptive Implants
  • Transmucosal
    • Oral (Buccal and Sublingual)
    • Others (Rectal and Vaginal)

Geographic analysis

  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Russia
  • Rest of Europe (RoE)

Table of Contents

1. INTRODUCTION

  • 1.1. KEY TAKE-AWAYS
  • 1.2. REPORT DESCRIPTION
  • 1.3. MARKETS COVERED
  • 1.4. STAKEHOLDERS
  • 1.5. RESEARCH METHODOLOGY
    • 1.5.1. MARKET SIZE
    • 1.5.2. MARKET SHARE
    • 1.5.3. KEY DATA POINTS FROM SECONDARY SOURCES
    • 1.5.4. KEY DATA POINTS FROM PRIMARY SOURCES
    • 1.5.5. ASSUMPTIONS

2. EXECUTIVE SUMMARY

3. MARKET OVERVIEW

  • 3.1. INTRODUCTION
  • 3.2. MARKET DYNAMICS
    • 3.2.1. DRIVERS
      • 3.2.1.1. Patent Cliff and Increased Competition to Increase Adoption Rate
      • 3.2.1.2. Improving Patient Compliance and Acceptability, an Impetus to the Drug Delivery Systems Market
      • 3.2.1.3. Increasing Focus on Pediatric and Geriatric Patients to Boost Overall Growth
      • 3.2.1.4. Increasing Incidence of Chronic Diseases like Cancer and Diabetes to Enhance Demand for Drug Delivery Technologies
      • 3.2.1.5. Higher Premature Mortality Rates in Eastern Europe and Russia Suggests need for Better Medication
    • 3.2.2. RESTRAINTS
      • 3.2.2.1. Drug Failures and Recalls Mar Market Growth
      • 3.2.2.2. Technical Barriers Restrict Growth
    • 3.2.3. OPPORTUNITIES
      • 3.2.3.1. Collaborations Between Pharmaceutical Companies and Drug Delivery Firms
      • 3.2.3.2. Self-administration and Home Care Drug Delivery Devices
      • 3.2.3.3. Expanding Therapeutic Applications of Drug Delivery Technologies
    • 3.2.4. TARGETED DRUG DELIVERY
      • 3.2.4.1. Passive Systems Contribute 60% to the Targeted Drug Delivery Market
      • 3.2.4.2. Active Targeted Drug Delivery has Major Applications in Cancer Therapy
      • 3.2.4.3. Companies Focus on Novel Targeted Drug Delivery
    • 3.2.5. BURNING ISSUES
      • 3.2.5.1. Striking Right Partnerships
      • 3.2.5.2. Improving the Bioavailability of Drugs
  • 3.3. REGULATORY AFFAIRS
    • 3.3.1. EUROPEAN UNION REGULATORY FRAMEWORK
    • 3.3.2. GERMANY
      • 3.3.2.1. Bundesministerium für Gesundheit (Ministry of Health)
      • 3.3.2.2. Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices)
    • 3.3.3. U.K.
      • 3.3.3.1. The Medicines and Healthcare products Regulatory Agency (MHRA)
    • 3.3.4. FRANCE
      • 3.3.4.1. Agence Nationale de Sécurité du Médicament et des Produits de Santé (National Agency for the Safety of Medicines and Health Products)
    • 3.3.5. SPAIN
      • 3.3.5.1. Agencia Espagnola de Medicamentos y Productos Sanitarios (Spanish Medicines and Health Products Agency)
    • 3.3.6. ITALY
      • 3.3.6.1. Agenzia Italiana del Farmaco (Italian Medicines Agency)
    • 3.3.7. RUSSIA
      • 3.3.7.1. Association of International Pharmaceutical Manufacturers (AIPM)
  • 3.4. REIMBURSEMENT SCENARIO IN THE EUROPEAN UNION
  • 3.5. MARKET SEGMENTATION
  • 3.6. PORTER'S FIVE FORCES ANALYSIS
  • 3.7. VALUE CHAIN ANALYSIS
  • 3.8. MARKET SHARE ANALYSIS
    • 3.8.1. PULMONARY DRUG DELIVERY
    • 3.8.2. INJECTABLE DRUG DELIVERY
      • 3.8.2.1. Conventional Injection Devices
      • 3.8.2.2. Self-injection Devices

4. GLOBAL DRUG DELIVERY MARKET, BY TECHNOLOGY

  • 4.1. INTRODUCTION
  • 4.2. OPPORTUNITY MATRIX
  • 4.3. ORAL DRUG DELIVERY
    • 4.3.1. CONTROLLED RELEASE
    • 4.3.2. ORODISPERSIBLE TABLETS (ODT) AND TASTE MASKING
    • 4.3.3. OTHERS
  • 4.4. PULMONARY DRUG DELIVERY
    • 4.4.1. THERAPEUTIC APPLICATIONS OF PULMONARY DELIVERY
    • 4.4.2. METERED DOSE INHALERS (MDI)
    • 4.4.3. DRY POWDER INHALERS (DPI)
    • 4.4.4. NEBULIZERS
  • 4.5. TRANSDERMAL DRUG DELIVERY
    • 4.5.1. PASSIVE TRANSDERMAL DRUG DELIVERY
      • 4.5.1.1. Matrix System
      • 4.5.1.2. Reservoir System
    • 4.5.2. ACTIVE TRANSDERMAL DRUG DELIVERY
      • 4.5.2.1. Microporation
      • 4.5.2.2. Iontophoresis
      • 4.5.2.3. Others
  • 4.6. INJECTABLE DRUG DELIVERY
    • 4.6.1. CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
      • 4.6.1.1. Fillable
      • 4.6.1.2. Prefilled
    • 4.6.2. SELF-INJECTION DEVICES
      • 4.6.2.1. Pen Injectors
      • 4.6.2.2. Needle-free Injectors
      • 4.6.2.3. Auto Injectors
    • 4.6.3. OTHERS
  • 4.7. OCULAR DRUG DELIVERY
    • 4.7.1. EYE DROPS
    • 4.7.2. OINTMENTS AND GELS
    • 4.7.3. OTHERS
  • 4.8. NASAL DRUG DELIVERY
    • 4.8.1. NASAL SPRAYS
    • 4.8.2. NASAL INHALERS
    • 4.8.3. NASAL DROPS
    • 4.8.4. OTHERS
  • 4.9. TOPICAL DRUG DELIVERY
    • 4.9.1. SEMI-SOLID FORMULATIONS
    • 4.9.2. LIQUID FORMULATIONS
    • 4.9.3. SOLID FORMULATIONS
  • 4.10. IMPLANTABLE DRUG DELIVERY
    • 4.10.1. DRUG- ELUTING STENTS
    • 4.10.2. IMPLANTABLE INFUSION PUMPS
    • 4.10.3. CONTRACEPTIVE IMPLANTS
    • 4.10.4. INTRAOCULAR IMPLANTS
    • 4.10.5. BRACHYTHERAPY SEEDS
  • 4.11. TRANSMUCOSAL DRUG DELIVERY
    • 4.11.1. ORAL (BUCCAL AND SUBLINGUAL)
    • 4.11.2. OTHERS (RECTAL, VAGINAL)

5. GEOGRAPHIC ANALYSIS

  • 5.1. INTRODUCTION
  • 5.2. GERMANY
  • 5.3. FRANCE
  • 5.4. U.K.
  • 5.5. SPAIN
  • 5.6. ITALY
  • 5.7. RUSSIA
  • 5.8. REST OF EUROPE (ROE)

6. COMPETITIVE LANDSCAPE

  • 6.1. INTRODUCTION
  • 6.2. NEW PRODUCT LAUNCH
  • 6.3. AGREEMENTS, COLLABORATIONS, JOINT VENTURES & PARTNERSHIPS
  • 6.4. MERGERS & ACQUISITIONS
  • 6.5. OTHER DEVELOPMENTS

7. COMPANY PROFILES (Overview, Financials, Products & Services, Strategy, & Developments)*

  • 7.1. 3M COMPANY
  • 7.2. ALKERMES, INC.
  • 7.3. BECTON, DICKINSON AND COMPANY
  • 7.4. CIMA LABS
  • 7.5. DALI MEDICAL DEVICES
  • 7.6. FOAMIX
  • 7.7. JOHNSON & JOHNSON, INC.
  • 7.8. PSIVIDA CORPORATION
  • 7.9. SKYEPHARMA PLC
  • 7.10. VALEANT PHARMACEUTICALS
  • 7.11. YPSOMED HOLDING AG

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

LIST OF TABLES

  • TABLE 1. EUROPEAN DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017($BILLION)
  • TABLE 2. EUROPEAN DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017($BILLION)
  • TABLE 3. EUROPEAN ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 4. EUROPEAN ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 5. EUROPEAN CONTROLLED RELEASE DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 6. EUROPEAN ODT &TASTE-MASKING MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 7. EUROPEAN OTHER ORAL DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 8. EUROPEAN PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 9. EUROPEAN PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 10. COMPARATIVE OVERVIEW OF PULMONARY DRUG DELIVERY DEVICES
  • TABLE 11. EUROPEAN METERED DOSE INHALATION (MDI) MARKET, BY COUNTRY,2010 - 2017 ($MILLION)
  • TABLE 12. EUROPEAN DRY POWDER INHALATION (DPI) MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 13. EUROPEAN NEBULIZERS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 14. EUROPEAN TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION)
  • TABLE 15. EUROPEAN TRANSDERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 16. EUROPEAN PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)
  • TABLE 17. EUROPEAN PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 18. EUROPEAN ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 19. EUROPEAN ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 20. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2010 - 2017 ($MILLION)
  • TABLE 21. EUROPEAN INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 22. EUROPEAN CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2010 - 2017 ($MILLION)
  • TABLE 23. EUROPEAN CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 24. EUROPEAN SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 - 2017 ($MILLION)
  • TABLE 25. EUROPEAN SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 26. EUROPEAN OTHER INJECTORS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 27. EUROPEAN OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 28. EUROPEAN OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 29. EUROPEAN EYE DROPS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 30. OINTMENT & GEL DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 31. EUROPEAN OTHER OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 32. EUROPEAN NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 33. EUROPEAN NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 34. EUROPEAN NASAL SPRAY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 35. EUROPEAN NASAL INHALER MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 36. EUROPEAN NASAL DROPS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 37. EUROPEAN OTHER NASAL DELIVERY FORMULATIONS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 38. EUROPEAN TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 39. EUROPEAN TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 40. EUROPEAN SEMI-SOLID TOPICAL FORMULATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 41. EUROPEAN LIQUID TOPICAL FORMULATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 42. EUROPEAN SOLID TOPICAL FORMULATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 43. EUROPEAN IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE, 2010 - 2017 ($MILLION)
  • TABLE 44. EUROPEAN IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 45. EUROPEAN DRUG-ELUTING STENTS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 46. EUROPEAN IMPLANTABLE INFUSION PUMPS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 47. EUROPEAN CONTRACEPTIVE IMPLANTS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 48. EUROPEAN INTRAOCULAR IMPLANTS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 49. EUROPEAN BRACHYTHERAPY SEEDS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 50. EUROPEAN TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION)
  • TABLE 51. EUROPEAN TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 52. EUROPEAN ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 53. EUROPEAN OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 - 2017 ($MILLION)
  • TABLE 54. GERMANY: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION)
  • TABLE 55. GERMANY: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 56. GERMANY: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 57. GERMANY: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION)
  • TABLE 58. GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 59. GERMANY: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 60. GERMANY: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 010 - 2017 ($MILLION)
  • TABLE 61. GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 62. GERMANY: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 63. GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION)
  • TABLE 64. FRANCE: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION)
  • TABLE 65. FRANCE: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 66. FRANCE: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 67. FRANCE: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION)
  • TABLE 68. FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 69. FRANCE: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 70. FRANCE: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 71. FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 72. FRANCE: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 73. FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION)
  • TABLE 74. U.K.: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION)
  • TABLE 75. U.K.: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 76. U.K.: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 77. U.K.: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION)
  • TABLE 78. U.K.: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 79. U.K.: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 80. U.K.: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 81. U.K.: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 82. U.K.: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 83. U.K.: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION)
  • TABLE 84. SPAIN: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION)
  • TABLE 85. SPAIN: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 86. SPAIN: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 87. SPAIN: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION)
  • TABLE 88. SPAIN: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 89. SPAIN: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 90. SPAIN: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 91. SPAIN: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 92. SPAIN: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 93. SPAIN: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION)
  • TABLE 94. ITALY: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION)
  • TABLE 95. ITALY: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 96. ITALY: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 97. ITALY: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION)
  • TABLE 98. ITALY: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 99. ITALY: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 100. ITALY: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 101. ITALY: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 102. ITALY: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 103. ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION)
  • TABLE 104. RUSSIA: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION)
  • TABLE 105. RUSSIA: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 106. RUSSIA: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 107. RUSSIA: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION)
  • TABLE 108. RUSSIA: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 109. RUSSIA: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 110. RUSSIA: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 111. RUSSIA: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 112. RUSSIA: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 113. RUSSIA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION)
  • TABLE 114. ROE: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 - 2017 ($MILLION)
  • TABLE 115. ROE: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 116. ROE: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 117. ROE: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 - 2017 ($MILLION)
  • TABLE 118. ROE: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 - 2017 ($MILLION)
  • TABLE 119. ROE: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 120. ROE: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 121. ROE: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 - 2017 ($MILLION)
  • TABLE 122. ROE: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 - 2017 ($MILLION)
  • TABLE 123. ROE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 - 2017 ($MILLION)
  • TABLE 124. NEW PRODUCT LAUNCH, 2010 - 2012
  • TABLE 125. AGREEMENTS, COLLABORATIONS, JOINT VENTURES & PARTNERSHIPS, 2011 -2012
  • TABLE 126. MERGERS & ACQUISITIONS, 2011 -2013
  • TABLE 127. OTHER DEVELOPMENTS, 2010 - 2013
  • TABLE 128. 3M COMPANY: TOTAL REVENUE, BY SEGMENT, 2009 - 2011 ($MILLION)
  • TABLE 129. 3M COMPANY: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
  • TABLE 130. ALKERMES: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION)
  • TABLE 131. BECTON, DICKINSON: TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($MILLION)
  • TABLE 132. BECTON, DICKINSON: MEDICAL DIVISION TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($MILLION)
  • TABLE 133. BECTON, DICKINSON: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012($MILLION)
  • TABLE 134. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($MILLION)
  • TABLE 135. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012 ($MILLION)
  • TABLE 136. JOHNSON & JOHNSON, INC.: TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($MILLION)
  • TABLE 137. JOHNSON & JOHNSON, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012 ($MILLION)
  • TABLE 138. VALEANT PHARMACEUTICALS: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2012 ($MILLION)
  • TABLE 139. YPSOMED: TOTAL REVENUE, BY SEGMENT, 2009 - 2011 ($MILLION)
  • TABLE 140. YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2009 ($MILLION)
  • TABLE 141. YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2010 - 2011 ($MILLION)

LIST OF FIGURES

  • FIGURE 1. EUROPEAN DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2017
  • FIGURE 2. EUROPEAN DRUG DELIVERY MARKET, BY COUNTRY, 2010 - 2017 ($BILLION)
  • FIGURE 3. MARKET DYNAMICS
  • FIGURE 4. EUROPEAN DRUG DELIVERY MARKET SEGMENTATION
  • FIGURE 5. PORTER'S FIVE FORCES ANALYSIS FOR DRUG DELIVERY MARKET
  • FIGURE 6. VALUE CHAIN ANALYSIS
  • FIGURE 7. EUROPEAN PULMONARY DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
  • FIGURE 8. EUROPEAN CONVENTIONAL INJECTION DEVICES: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
  • FIGURE 9. EUROPEAN CONVENTIONAL INJECTABLE DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
  • FIGURE 10. OPPORTUNITY MATRIX: EUROPEAN DRUG DELIVERY TECHNOLOGIES MARKET (2012)
  • FIGURE 11. KEY GROWTH STRATEGIES, 2010 - 2013
  • FIGURE 12. 3M COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
  • FIGURE 13. ALKERMES: TOTAL REVENUE AND R&D EXPENDITURE, 2009 - 2011 ($MILLION)
  • FIGURE 14. BECTON, DICKINSON: TOTAL REVENUE AND R&D EXPENDITURE, 2010 - 2012 ($MILLION)
  • FIGURE 15. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES, 2010 - 2012 ($MILLION)
  • FIGURE 16. JOHNSON & JOHNSON, INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 - 2012 ($MILLION)
  • FIGURE 17. PSIVIDA CORPORATION: TOTAL REVENUE, 2009 - 2011 ($MILLION)
  • FIGURE 18. SKYEPHARMA PLC: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
  • FIGURE 19. VALEANT PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2010 - 2012 ($MILLION)
  • FIGURE 20. YPSOMED: TOTAL REVENUE AND R&D EXPENSES, 2009 - 2011 ($MILLION)
Back to Top